Sino Biopharmaceutica Valuation
| SBHMY Stock | USD 9.05 0.00 0.00% |
At this time, the company appears to be fairly valued. Sino Biopharmaceutical has a current Real Value of $8.94 per share. The regular price of the company is $9.05. Our model measures the value of Sino Biopharmaceutical from inspecting the company fundamentals such as Shares Outstanding of 940.69 M, operating margin of 0.16 %, and Return On Equity of 0.29 as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Sino Biopharmaceutica's price fluctuation is somewhat reliable at this time. Calculation of the real value of Sino Biopharmaceutical is based on 3 months time horizon. Increasing Sino Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sino Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sino Pink Sheet. However, Sino Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.05 | Real 8.94 | Hype 9.05 | Naive 9.23 |
The intrinsic value of Sino Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sino Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sino Biopharmaceutical Ltd helps investors to forecast how Sino pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sino Biopharmaceutica more accurately as focusing exclusively on Sino Biopharmaceutica's fundamentals will not take into account other important factors: Sino Biopharmaceutica Total Value Analysis
Sino Biopharmaceutical Ltd is at this time expected to have takeover price of 10.34 B with market capitalization of 10.88 B, debt of 5.21 B, and cash on hands of 15.67 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sino Biopharmaceutica fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.34 B | 10.88 B | 5.21 B | 15.67 B |
Sino Biopharmaceutica Investor Information
The book value of the company was at this time reported as 32.7. The company has Price/Earnings To Growth (PEG) ratio of 0.53. Sino Biopharmaceutical last dividend was issued on the 6th of September 2022. The entity had 1:1 split on the 14th of August 2020. Based on the key measurements obtained from Sino Biopharmaceutica's financial statements, Sino Biopharmaceutical Ltd is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Sino Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sino Biopharmaceutica has an asset utilization ratio of 44.37 percent. This suggests that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Sino Biopharmaceutical Ltd is more efficient with each dollar of assets it utilizes for everyday operations.Sino Biopharmaceutica Profitability Analysis
The company reported the revenue of 26.86 B. Net Income was 14.61 B with profit before overhead, payroll, taxes, and interest of 21.53 B.About Sino Biopharmaceutica Valuation
Our relative valuation model uses a comparative analysis of Sino Biopharmaceutica. We calculate exposure to Sino Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sino Biopharmaceutica's related companies.Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States.
8 Steps to conduct Sino Biopharmaceutica's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sino Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sino Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sino Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sino Biopharmaceutica's revenue streams: Identify Sino Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sino Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sino Biopharmaceutica's growth potential: Evaluate Sino Biopharmaceutica's management, business model, and growth potential.
- Determine Sino Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sino Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Sino Biopharmaceutica Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 18.8 B | |
| Quarterly Earnings Growth Y O Y | -0.865 | |
| Forward Price Earnings | 20.8333 | |
| Retained Earnings | 27.2 B |
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.